Drug Information Association Logo
« Back to Listing

Impact of Bayesian Methods in Drug Development with a Focus on Comparative Effectiveness Research

Track:
Statistical Science and Quantitative Thinking

Day & Time:
June 17, 10:30AM - 12:00PM (Pacific Standard Time)

Session Number:
247

Room Number:
5B

Level:
Intermediate

Type:
Forum

Title:
Impact of Bayesian Methods in Drug Development with a Focus on Comparative Effectiveness Research

Chair(s):
Karen Lynn Price, PhD, MA
Research Advisor
Eli Lilly and Company, United States

Description:
This forum will provide an overview of how Bayesian methods are used in practice, with particular emphasis on applications in comparative effectiveness research. We will focus on how such approaches can improve efficiency and provide clear quantitative development decisions.

This forum has been developed by the DIA Bayesian Scientific Working Group.

Learning Objective(s):
Describe the efforts of the DIA Bayesian Scientific Working Group; Examine the value of the Bayesian approach across drug development, with a focus on comparative effectiveness research (CER); Discuss gaps in the use of Bayesian methods for CER including ways to meet gaps; Identify opportunities to collaborate in the future with the CER Scientific Working Group and Evidence-based Medicine Community, via open conversation across membership.

Presentation(s) & Speaker(s):
Bayesian Evidence Synthesis and Network Meta-Analysis in Context of CER
Bradley P. Carlin, PhD, MS
Professor and Head of Biostatistics
University of Minnesota, United States

FDA Perspective
Ram Tiwari, PhD
Associate Director, Office of Biostatistics, OTS, CDER
FDA, United States

Panelist
Matthew D. Rotelli, PhD
Director, Global PK/PD and Pharmacometrics, Bio-Medicines
Eli Lilly and Company, United States